Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis

Cardiovascular Research

Volumn 101, Issue 2, 2014, Pages 187-193

  Stanke Labesque, Françoise ^a,b,c   Pépin, Jean Louis ^a,b,c   Gautier Veyret, Elodie ^a,b,c   Lévy, Patrick ^a,b,c   Bäck, Magnus ^d,e  

^a UNIV GRENOBLE ALPES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c University Grenoble Alpes   (France)

^d KAROLINSKA INSTITUTE   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Intermittent hypoxia; Leukotrienes; Obesity

Indexed keywords

LEUKOTRIENE;

ATHEROSCLEROSIS; CHRONIC INTERMITTENT HYPOXIA; HUMAN; INTERMITTENT HYPOXIA; OBESITY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REVIEW; SLEEP DISORDERED BREATHING;

ATHEROSCLEROSIS; INTERMITTENT HYPOXIA; LEUKOTRIENES; OBESITY;

ANIMALS; ANOXIA; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CONFOUNDING FACTORS (EPIDEMIOLOGY); GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; LEUKOTRIENES; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION; SLEEP APNEA, OBSTRUCTIVE; TRANSCRIPTION, GENETIC;

EID: 84893113499     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt247     Document Type: Review

References (63)

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleepdisordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-1235
2. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study. Lancet 2005;365:1046-1053
3. Yaggi HK, Concato J, KernanWN,Lichtman JH, BrassLM, MohseninV. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034-2041
4. Baguet JP, Hammer L, Levy P, Pierre H, Launois S, Mallion JM et al. The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence. Chest 2005; 128:3407-3412
5. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:613-618
6. Saletu M, Nosiska D, Kapfhammer G, LalouschekW, Saletu B, Benesch Tet al. Structural and serum surrogate markers of cerebrovascular disease in obstructive sleep apnea (OSA): Association of mild OSA with early atherosclerosis. J Neurol 2006;253:746-752
7. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea.AmJ Respir Crit Care Med 2007;176:706-712
8. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 2006;1:297-329
9. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-325
10. Rouzer CA, Kargman S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J Biol Chem 1988;263:10980-10988
11. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990;343:282-284
12. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 1987;237:1171-1176
13. Back M, Dahlen SE, Drazen JM, Evans JF, Serhan CN, Shimizu T et al. International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev 2011;63:539-584
14. Back M, Hansson GK. Leukotriene receptors in atherosclerosis. Ann Med 2006;38: 493-502
15. Sala A, Folco G, Murphy RC. Transcellular biosynthesis of eicosanoids. Pharmacol Rep 2010;62:503-510
16. Eaton A, Nagy E, Pacault M, Fauconnier J, Back M. Cysteinyl leukotriene signaling through perinuclear CysLT(1) receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression. J Mol Med (Berl) 2012;90: 1223-1231
17. Shen Y, XuZ, Shen K. Urinary leukotriene E4, obesity, and adenotonsillar hypertrophy in Chinese children with sleep disordered breathing. Sleep 2011;34:1135-1041
18. Stanke-Labesque F, Back M, Lefebvre B, Tamisier R, Baguet JP, Arnol N et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: Effects of obesity and hypoxia. J Allergy Clin Immunol 2009;124:364-370, 370 e1-e2
19. GoldbartAD, Krishna J, Li RC, Serpero LD, Gozal D. Inflammatory mediators in exhaled breath condensate of children with obstructive sleep apnea syndrome. Chest 2006;130: 143-148
20. Lefebvre B, Pepin JL, Baguet JP, Tamisier R, Roustit M, Riedweg K et al. Leukotriene B4: Early mediator of atherosclerosis in obstructive sleep apnoea? Eur Respir J 2008;32: 113-120
21. Stanke-Labesque F, Pepin JL, de Jouvencel T, Arnaud C, Baguet JP, PetriMH et al. Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J Lipid Res 2012;53:1944-1951
22. Kaditis AG, Alexopoulos E, Chaidas K, Ntamagka G, Karathanasi A, Tsilioni I et al. Urine concentrations of cysteinyl leukotrienes in children with obstructive sleep-disordered breathing. Chest 2009;135:1496-1501
23. Back M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther 2009;23:41-48
24. Lavie L. Obstructive sleep apnoea syndrome - An oxidative stress disorder. Sleep Med Rev 2003;7:35-51
25. Svatikova A,Wolk R,Wang HH, Otto ME, Bybee KA, Singh RJ et al. Circulating free nitrotyrosine in obstructive sleep apnea. Am J Physiol Regul Integr Comp Physiol 2004;287: R284-R287
26. Ohga E, TomitaT,Wada H,Yamamoto H, NagaseT, Ouchi Y. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 2003;94:179-184
27. Schulz R, Mahmoudi S, Hattar K, Sibelius U, Olschewski H, Mayer K et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000;162(2 Pt 1):566-570
28. Shamsuzzaman AS, Winnicki M, Lanfranchi P,Wolk R, Kara T, Accurso V et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002;105: 2462-2464
29. Werz O, Szellas D, Steinhilber D. Reactive oxygen species released from granulocytes stimulate 5-lipoxygenase activity in a B-lymphocytic cell line. Eur J Biochem 2000;267: 1263-1269
30. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002;165:934-939
31. Li RC, Haribabu B, Mathis SP, Kim J, Gozal D. Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis. Am J Respir Crit Care Med 2011;184:124-131
32. Chiang N, Gronert K, Clish CB, O'Brien JA, FreemanMW, Serhan CN. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 1999;104:309-316
33. Ichinose F, Ullrich R, Sapirstein A, Jones RC, Bonventre JV, Serhan CN et al. Cytosolic phospholipase A(2) in hypoxic pulmonary vasoconstriction. J Clin Invest 2002;109: 1493-1500
34. Gonsalves CS, Kalra VK. Hypoxia-mediated expression of 5-lipoxygenase-activating protein involves HIF-1alpha and NF-kappaB and microRNAs 135a and 199a-5p. J Immunol 2010;184:3878-3888
35. Nobili E, Salvado MD, Folkersen L, Castiglioni L, Kastrup J,Wetterholm Aet al. Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease. PLoS One 2012;7:e41786
36. Gautier E, Arnaud C, Back M, Pepin JL, Petri MH, Baguet JP et al. Intermittent hypoxia activated cyclooxygenase pathway: Role in atherosclerosis. Eur Respir J 2012;42: 404-413
37. Back M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 2009;15:3116-3132
38. Hoyer FF, Albrecht L, Nickenig G, Muller C. Selective inhibition of leukotriene receptor BLT-2 reduces vascular oxidative stress and improves endothelial function in ApoE -/- mice. Mol Cell Biochem 2012;359:25-31
39. Tamaki S, Yamauchi M, Fukuoka A, Makinodan K, Koyama N, TomodaK et al. Production of inflammatory mediators by monocytes in patients with obstructive sleep apnea syndrome. Intern Med 2009;48:1255-1262
40. Ketelhuth DF, Back M. The role of matrix metalloproteinases in atherothrombosis. Curr Atheroscler Rep 2011;13:162-169
41. Dyugovskaya L, Polyakov A, Lavie P, Lavie L. Delayed neutrophil apoptosis in patients with sleep apnea. Am J Respir Crit Care Med 2008;177:544-554
42. Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 2005;102:17501-17506
43. Hlawaty H, Jacob MP, Louedec L, Letourneur D, Brink C, Michel JB et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol 2009;29:518-524
44. Provost P, Borgeat P, Merhi Y. Platelets, neutrophils, and vasoconstriction after arterial injury by angioplasty in pigs: Effects of MK-886, a leukotriene biosynthesis inhibitor. Br J Pharmacol 1998;123:251-258
45. Yumino D, Tsurumi Y, Takagi A, Suzuki K, Kasanuki H. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J Cardiol 2007;99:26-30
46. Capra V, Back M, Barbieri SS, Camera M, Tremoli E, Rovati GE. Eicosanoids and their drugs in cardiovascular diseases: Focus on atherosclerosis and stroke. Med Res Rev 2013;33:364-438
47. Hasegawa S, Ichiyama T, Hashimoto K, Suzuki Y, Hirano R, Fukano R et al. Functional expression of cysteinyl leukotriene receptors on human platelets. Platelets 2010;21: 253-259
48. Testelmans D, Tamisier R, Barone-Rochette G, Baguet JP, Roux-Lombard P, Pepin JL et al. Profile of circulating cytokines: Impact of OSA, obesity and acute cardiovascular events. Cytokine 2013;62:210-216
49. Back M, Sultan A, Ovchinnikova O, Hansson GK. 5-Lipoxygenase-activating protein: A potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 2007;100:946-949
50. Mothe-Satney I, Filloux C, Amghar H, Pons C, Bourlier V, Galitzky J et al. Adipocytes secrete leukotrienes: Contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes 2012;61:2311-2319
51. Bonsignore MR, McNicholas WT, Montserrat JM, Eckel J. Adipose tissue in obesity and obstructive sleep apnoea. Eur Respir J 2012;39:746-767
52. Goldbart AD, Goldman JL, Veling MC, Gozal D. Leukotriene modifier therapy for mild sleep-disordered breathing in children. Am J Respir Crit Care Med 2005;172:364-370
53. Goldbart AD, Goldman JL, Li RC, Brittian KR, Tauman R, Gozal D. Differential expression of cysteinyl leukotriene receptors 1 and 2 in tonsils of children with obstructive sleep apnea syndrome or recurrent infection. Chest 2004;126:13-18
54. Dayyat E, Serpero LD, Kheirandish-Gozal L, Goldman JL, Snow A, Bhattacharjee R et al. Leukotriene pathways and in vitro adenotonsillar cell proliferation in children with obstructive sleep apnea. Chest 2009;135:1142-1149
55. Tsaoussoglou M, Lianou L, Maragozidis P, Hatzinikolaou S, Mavromati M, Orologas N et al. Cysteinyl leukotriene receptors in tonsillar B- and T-lymphocytes from children with obstructive sleep apnea. Sleep Med 2012;13:879-885
56. Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: A double-blind, placebo-controlled study. Pediatrics 2012;130:e575-e580
57. Riccioni G, Back M. Leukotrienes as modifiers of preclinical atherosclerosis? Scientific-WorldJournal 2012;2012:490968
58. Tardif JC, Lallier PL, Ibrahim R, Gregoire JC, Nozza A, CossetteMet al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010;3:298-307
59. Ingelsson E, Yin L, Back M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol 2012;129:702-707 e2
60. Craig SE, Kohler M, Nicoll D, Bratton DJ, Nunn A, Davies R et al. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: The MOSAIC randomised controlled trial. Thorax 2012;67:1090-1096
61. Pepin JL, Tamisier R, Levy P. Obstructive sleep apnoea and metabolic syndrome: Put CPAP efficacy in a more realistic perspective. Thorax 2012;67:1025-1027
62. Pepin JL, Tamisier R, Barone-Rochette G, Launois SH, Levy P, Baguet JP. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010;182:954-960
63. Feng J, Zhang D, Chen B. Endothelial mechanisms of endothelial dysfunction in patients with obstructive sleep apnea. Sleep Breath 2012;16:283-294